The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Reclassification of serous ovarian carcinoma by a 2‐tier system: A Gynecologic Oncology Group Study
Open accessAbstract
BACKGROUND: A study was undertaken to use the 2‐tier system to reclassify the grade of serous ovarian tumors previously classified using the International Federation of Gynecology and Obstetrics (FIGO) 3‐tier system and determine the progression‐free survival (PFS) and overall survival (OS) of patients treated on Gynecologic Oncology Group (GOG) Protocol 158. METHODS: The authors retrospectively reviewed demographic, pathologic, and survival data of 290 patients with stage III serous ovarian carcinoma treated with surgery and chemotherapy on GOG Protocol 158, a cooperative multicenter group trial. A blinded pathology review was performed by a panel of 6 gynecologic pathologists to verify histology and regrade tumors using the 2‐tier system. The association of tumor grade with PFS and OS was assessed. RESULTS: Of 241 cases, both systems demonstrated substantial agreement when combining FIGO grades 2 and 3 (overall agreement, 95%; kappa statistic, 0.68). By using the 2‐tier system, patients with low‐grade versus high‐grade tumors had significantly longer PFS (45.0 vs 19.8 months, respectively; P = .01). By using FIGO criteria, median PFS for patients with grade 1, 2, and 3 tumors was 37.5, 19.8, and 20.1 months, respectively (P = .07). There was no difference in clinical outcome in patients with grade 2 or 3 tumors in multivariate analysis. Woman with high‐grade versus low‐grade tumors demonstrated significantly higher risk of death (hazard ratio, 2.43; 95% confidence interval, 1.17‐5.04; P = .02). CONCLUSIONS: Women with high‐grade versus low‐grade serous carcinoma of the ovary are 2 distinct patient populations. Adoption of the 2‐tier grading system provides a simple yet precise framework for predicting clinical outcomes. Cancer 2012;118: 3087–94. © 2011 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Singer, G., Stöhr, R., Cope, L., Dehari, R., Hartmann, A., Cao, D.-F., Wang, T.-L., Kurman, R. J., & Shih, I.-M. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000146025.91953.8d · Cited by 408
Cited by
Ledermann, J. A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., & Sessa, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt333 · Cited by 1,104
Ultrasensitive detection of circulating exosomes with a 3D-nanopatterned microfluidic chip
Zhang, P., Zhou, X., He, M., Shang, Y., Tetlow, A. L., Godwin, A. K., & Zeng, Y. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0356-9 · Cited by 554
Cancer of the ovary, fallopian tube, and peritoneum: 2021 update
Berek, J. S., Renz, M., Kehoe, S., Kumar, L., & Friedlander, M. (2021) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13878 · Cited by 514
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022: Featured Updates to the NCCN Guidelines
Armstrong, D. K., Alvarez, R. D., Backes, F. J., Bakkum-Gamez, J. N., Barroilhet, L., Behbakht, K., Berchuck, A., Chen, L.-M., Chitiyo, V. C., Cristea, M., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0047 · Cited by 401
Self-citationCancer of the ovary, fallopian tube, and peritoneum
Berek, J. S., Kehoe, S. T., Kumar, L., & Friedlander, M. (2018) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12614 · Cited by 327
Metadata
- Authors
- Bodurka, D. C., Deavers, M. T., Tian, C., Sun, C. C., Malpica, A., Coleman, R. L., Lu, K. H., Sood, A. K., Birrer, M. J., Ozols, R., Baergen, R., Emerson, R. E., Steinhoff, M., Behmaram, B., Rasty, G., & Gershenson, D. M.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2011-11-09
- Volume
- 118
- Issue
- 12
- Pages
- 3087-3094
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1571075157
- Cited by
- 160
- References
- 1
- FWCI
- 12.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reclassification of serous ovarian carcinoma by a 2‐tier system: A Gynecologic Oncology Group Study. https://app.cochat.ai/papers/10.1002/cncr.26618
- The paper
- Bodurka, D. C., Deavers, M. T., Tian, C., Sun, C. C., Malpica, A., Coleman, R. L., Lu, K. H., Sood, A. K., Birrer, M. J., Ozols, R., Baergen, R., Emerson, R. E., Steinhoff, M., Behmaram, B., Rasty, G., & Gershenson, D. M. (2012). Reclassification of serous ovarian carcinoma by a 2‐tier system: A Gynecologic Oncology Group Study. Cancer. https://doi.org/10.1002/cncr.26618
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.